First Update on Overall Survival, Progression-free Survival, and Time-to-deterioration of Health-related Quality of Life from the NETTER-1 Study: 177Lu-DOTATATE (Lutathera®) vs high dose octreotide in progressive midgut neuroendocrine tumors